Your browser doesn't support javascript.
loading
Combination Therapies against COVID-19.
Luo, Qunfeng; Zheng, Yunxi; Zhang, Jin.
Afiliación
  • Luo Q; School of Basic Medical Sciences, Nanchang University, 330047 Nanchang, Jiangxi, China.
  • Zheng Y; Queen Marry College, Nanchang University, 330047 Nanchang, Jiangxi, China.
  • Zhang J; School of Basic Medical Sciences, Nanchang University, 330047 Nanchang, Jiangxi, China.
Front Biosci (Landmark Ed) ; 27(9): 257, 2022 09 06.
Article en En | MEDLINE | ID: mdl-36224005
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of Coronavirus disease 2019 (COVID-19), which was announced as a pandemic leading to devastating economic and medical burden worldwide. The virus attacks the organ system across the body by binding to its receptor (for example, angiotensin converting enzyme 2) on the surface of the host cell of various organs. The patients present with a variety of pathological symptoms ranging from fever, cough and cytokine storm to acute respiratory distress syndrome (ARDS). Many combination therapies have been developed to combat the disease, via blocking one or more processes of the viral life cycle and/or relieving host complications simultaneously. In this review, the progress of those combination therapies containing at least one small molecule is updated. We believe it'll provide significant inspiration for further development of treatment strategy against SARS-CoV-2, especially its mutant variants.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 Límite: Humans Idioma: En Revista: Front Biosci (Landmark Ed) Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 Límite: Humans Idioma: En Revista: Front Biosci (Landmark Ed) Año: 2022 Tipo del documento: Article País de afiliación: China